Regenicin (OTCMKTS:RGIN) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Institutional and Insider Ownership
93.9% of OraSure Technologies shares are owned by institutional investors. 2.9% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Regenicin and OraSure Technologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|OraSure Technologies||$181.74 million||3.47||$20.40 million||$0.50||20.48|
OraSure Technologies has higher revenue and earnings than Regenicin.
Volatility and Risk
Regenicin has a beta of 3.93, suggesting that its stock price is 293% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Regenicin and OraSure Technologies, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OraSure Technologies has a consensus price target of $16.00, suggesting a potential upside of 56.25%. Given OraSure Technologies’ higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Regenicin.
This table compares Regenicin and OraSure Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
OraSure Technologies beats Regenicin on 9 of the 10 factors compared between the two stocks.
Regenicin Company Profile
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
OraSure Technologies Company Profile
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Receive News & Ratings for Regenicin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenicin and related companies with MarketBeat.com's FREE daily email newsletter.